Multiple Myeloma Clinical Trial
Evaluation of the Drug Plerixafor in Combination With Chemotherapy and G-CSF for Stem Cell Collection
Summary
The purpose of this study is to test whether the addition of the drug plerixafor to treatment with chemotherapy and G-CSF can better activate your bone marrow stem cells to improve the chances of transplant. The study will look for the activation of a certain type of blood cell, called CD34+ cells in patients who receive plerixafor, chemotherapy and G-CSF. The investigators will follow the number of patients that achieve the target numbers of CD34+ cells. The number of patients achieving the target level of CD34+ cells, and the total number of CD34+ cells, will be compared to the numbers in previous studies testing just chemotherapy and G-CSF, without plerixafor.
The investigators will also test the safety of the combination of plerixafor with chemotherapy and G-CSF and look at the success of the transplantation after 12 months.
Eligibility Criteria
Inclusion Criteria:
Age 18-70 years
Multiple myeloma (MM) or non-Hodgkin's lymphoma (NHL) patients in first or second complete or partial remission
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Up to 3 prior treatment regimens
Meet all eligibility requirements for autologous transplant
Adequate marrow function defined as white blood cells (WBC) >3,000; ANC >1,500/mm3; platelets >75,000/mm3
Adequate renal function defined as creatinine clearance > 30 mL/min by Cockcroft-Gault
Adequate liver function defined as aspartate aminotransferase (AST)/alanine aminotransferase (ALT)/bilirubin < 2 times upper limit of normal
Able to provide informed consent
Women not pregnant and agree to use contraception
Exclusion Criteria:
High risk co-morbidities for acute treatment complications (e.g., symptomatic coronary artery disease)
Brain metastases or carcinomatous meningitis
Previous treatment with high dose chemotherapy and autologous transplant
Previous attempt to collect B-hematopoietic progenitor cells (HPCs) following mobilization with growth factors alone, growth factors and chemotherapy, or plerixafor and growth factors
Acute infection or unexplained fever >38°C
Weight > 175% of ideal body weight as defined by the Devine equation
Experimental therapy within 4 weeks
Cytokine administration in the previous 14 days
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Atlanta Georgia, 30322, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.